DuPont (DD) SVP & General Counsel exercises 6,005 options and sells 6,005 shares

Rhea-AI Filing Summary

DuPont de Nemours, Inc. insider equity transaction: The company’s SVP & General Counsel reported an option exercise and share sale in DuPont common stock. On 11/28/2025, the executive exercised stock options covering 6,005 shares at an exercise price of $28 per share, converting them into common stock. On the same date, 6,005 common shares were sold at a price of $39.79 per share.

Following these transactions, the reporting person directly beneficially owned 112,101.1276 shares of DuPont common stock. The options exercised were part of a grant originally dated 02/03/2019, with an expiration date of 02/02/2026, and the remaining balance of these options is now reported as zero.

Insider Trade Summary

Net Seller: 6,005 shares ($238,939)

Net Sell 3 txns

Insider Hoover Erik T.

Role SVP & General Counsel

Sold 6,005 shs ($239K)

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy NQOs)	6,005	$0.00	--
Exercise	Common Stock	6,005	$28.00	$168K
Sale	Common Stock	6,005	$39.79	$239K

Holdings After Transaction: Stock Options (Right to Buy NQOs) — 0 shares (Direct); Common Stock — 118,106.13 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoover Erik T.

(Last) (First) (Middle)

CHESTNUT RUN PLAZA 730

974 CENTRE ROAD

(Street)

WILMINGTON DE 19805

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DuPont de Nemours, Inc. [ DD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
11/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/28/2025		M		6,005	A	$28	118,106.13	D
Common Stock	11/28/2025		S		6,005	D	$39.79	112,101.1276	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy NQOs)	$28	11/28/2025		M		6,005		02/03/2019(1)	02/02/2026	Common Stock	6,005	$0	0	D

Explanation of Responses:

1. Options become exercisable in three substantially equal installments beginning on the first anniversary of the grant; option shares may be used to satisfy withholding taxes.

Remarks:

	Paige Fleming By Power of Attorney	12/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did DuPont (DD) disclose in this Form 4 filing?

The filing reports that DuPont’s SVP & General Counsel exercised stock options for 6,005 shares at $28 per share and sold 6,005 common shares at $39.79 per share on 11/28/2025.

How many DuPont (DD) shares does the insider own after the reported transactions?

After the reported option exercise and share sale, the insider directly beneficially owns 112,101.1276 shares of DuPont common stock.

What type of derivative security did the DuPont (DD) insider exercise?

The insider exercised stock options (Right to Buy NQOs) with an exercise price of $28 per share, covering 6,005 shares of DuPont common stock.

What were the key dates for the DuPont (DD) stock options in this Form 4?

The stock options were from a grant dated 02/03/2019, had an expiration date of 02/02/2026, and were exercised on 11/28/2025.

Is the DuPont (DD) Form 4 filing made by one or multiple reporting persons?

The Form 4 is indicated as filed by one reporting person, who serves as DuPont’s SVP & General Counsel.

What is the relationship of the reporting person to DuPont (DD)?

The reporting person is an officer of DuPont, serving as SVP & General Counsel, as indicated in the filing.